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Introduction
Cardiovascular disease (CVD) is the leading cause of  morbidity and mortality worldwide, accounting for 
about 32% of  all global deaths (1, 2). CVD results from multifactorial causative mechanisms and con-
stitutes a high economic burden on society and the health care system. Typically, CVD, including coro-
nary artery disease, stroke, or peripheral artery disease, involves endothelial dysfunction resulting from a 
vascular injury and is characterized by progressive arterial thickening, leading ultimately to thrombosis 
and vascular occlusion. This atherosclerotic process starts with early lipid deposition in the inner layers 
of  the artery walls and progresses to late complications, such as fibrosis and calcification. While calci-
fication of  arterial intima is associated with plaque rupture and myocardial infarction, calcification of  
arterial media leads to vessel stiffening and increased pulse-wave velocity and reduces cardiac perfusion, 
with the consequence of  ventricular hypertrophy and heart failure (3, 4).
Although significant advancements have been made in understanding the pathophysiology of  CVD 
(5), there is still progress to be made to unravel the detailed molecular complexity of  the disease and to 
Although cardiovascular disease (CVD) is the leading cause of morbimortality worldwide, promising 
new drug candidates are lacking. We compared the arterial high-resolution proteome of patients 
with advanced versus early-stage CVD to predict, from a library of small bioactive molecules, drug 
candidates able to reverse this disease signature. Of the approximately 4000 identified proteins, 
100 proteins were upregulated and 52 were downregulated in advanced-stage CVD. Arachidonyl 
trifluoromethyl ketone (AACOCF3), a cytosolic phospholipase A2 (cPLA2) inhibitor was predicted 
as the top drug able to reverse the advanced-stage CVD signature. Vascular cPLA2 expression was 
increased in patients with advanced-stage CVD. Treatment with AACOCF3 significantly reduced 
vascular calcification in a cholecalciferol-overload mouse model and inhibited osteoinductive 
signaling in vivo and in vitro in human aortic smooth muscle cells. In conclusion, using a systems 
biology approach, we have identified a potentially new compound that prevented typical vascular 
calcification in CVD in vivo. Apart from the clear effect of this approach in CVD, such strategy should 
also be able to generate novel drug candidates in other complex diseases.
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transform this information into new drug candidates. The extreme complexity and multifactorial charac-
ter of  CVD has prompted researchers to shift from investigating already well-known candidate pathways 
or single molecules to unbiased omics-based studies (6). Omics allows the study of  the entire “system” 
simultaneously, leading to a better representation of  the complex molecular mechanism of  CVD (7) and, 
thus, ultimately enabling the major aim of  identifying truly novel CVD targets. This has resulted in a 
number of  recent omics studies in the field identifying potential biomarkers of  CVD (8) but not neces-
sarily resulting in novel drugs yet. The latter could be attributed to the fact that potential targets need to 
be transformed into drugs, which often takes a substantial amount of  time and effort, and/or that most 
studies employed genomic and transcriptomic strategies, which not necessarily translate to changes in 
proteins, the major drug targets (9).
As a response to the ever-increasing omics data and in an effort to target their optimal use for drug 
discovery, a number of  initiatives have evolved to create a shortcut associating omics molecular signatures 
to drugs and small compounds. The Connectivity Map (CMap) is the most advanced example of  this type 
of  approach (10), where 564 gene expression profiles from cultured human cells treated with 164 bioac-
tive small molecules were generated and associated via pattern-mining software. This resource was later 
updated to include associated signatures to 1,309 compounds (https://portals.broadinstitute.org/cmap/). 
Attempts have been made to use CMap in CVD but were limited to mouse models (11) or in vitro studies 
(12) or focused on human stem cells (13). Furthermore, none of  these studies tested the therapeutic validity 
of  the selected small CMap molecules.
To our knowledge this is the first effort to identify novel drugs in CVD using drug repurposing based on 
human molecular signatures. We generated a high-resolution human proteome signature of  advanced-stage 
CVD using peripheral artery samples that allowed the identification of  a potentially novel drug candidate, 
arachidonyl trifluoromethyl ketone (AACOCF3), a cytosolic phospholipase A2 (cPLA2) inhibitor. In vivo 
and in vitro investigations showed that AACOCF3 exerts a potent inhibitory action on arterial calcification.
Results
CVD patient clinical data used in vessel proteome analysis. For vessel proteome analysis of  CVD vessels, 
common iliac, external iliac, and superficial femoral arteries from 15 patients with early-stage CVD 
and 17 patients with advanced-stage CVD were employed (Table 1). Advanced-stage CVD patients had 
clear CVD phenotypes (vascular disease, left ventricular hypertrophy, angina pectoris, intermittent clau-
dication, myocardial infraction). These cardiovascular phenotypes were not found in early-stage CVD 
patients (Table 1). H&E staining (Figure 1, A and C) and von Kossa staining (Figure 1, B and D) con-
firmed intima media thickening and calcification in arteries from the advanced-stage CVD group com-
pared with early-stage CVD patients. Advanced-stage CVD patients were older than early-stage CVD 
patients. The female/male ratio was also different between the groups, with almost exclusively females 
in the early-stage CVD group. The advanced-stage CVD group had a higher proportion of  patients with 
hypertension, diabetes, and nicotine use. The medication use of  the 2 groups was very diverse, with no 
clear distinguishable features between the groups (Supplemental Table 3; supplemental material avail-
able online with this article; https://doi.org/10.1172/jci.insight.125638DS1).
Arterial protein signature of  advanced-stage CVD. Proteome analysis of  the arteries led to the detection of  
about 4000 proteins in total (2500–3500 proteins per patient, detected in at least 60% of  samples). Samples 
were analyzed in 2 batches, and only proteins that were significantly differentially expressed in 1 batch and 
displayed the same expression direction in the other batch were selected. This led to the selection of  152 pro-
teins, with 100 and 52 that were upregulated and downregulated in advanced-stage CVD, respectively (Sup-
plemental Table 4). The change in abundance of  selected proteins present in the CVD signature (SHMT1, 
EFEMP1, KDM5D: increase; GUCY1B2: decrease) was confirmed by Western blot analyses of  the arteries 
(Supplemental Figure 1), supporting in general the validity of  the CVD vessel proteome analysis.
Pathway analysis with the Reactome database (https://reactome.org/) revealed that these proteins main-
ly participated in signal transduction (37%); transcription (26%); metabolism (22%); immune system (22%); 
metabolism of proteins (21%); and developmental biology (18%). Among the 29 proteins involved in metab-
olism, 14 were related to lipid metabolism, including SREBF1, ATP-binding cassette subfamily A member 
2 (ABCA2), and PTB domain–containing engulfment adapter protein 1 (GULP1), involved in cholesterol 
synthesis and transport. The CVD signature also contains the protein AMBP, involved in calcium crystalliza-
tion, and EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1), involved in chondrogenesis.
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AACOCF3 as a potential drug candidate for CVD treatment. We next used this 152-protein signature to identi-
fy potentially new drug candidates for CVD treatment. Using CMap (10), we screened 1309 small molecules 
able to reverse this CVD signature in silico. Among the molecules of  the CMap database, 12 were predicted 
to significantly reverse the CVD signature (Table 2). Among these 12 molecules, arachidonyltrifluorometh-
ane, also called arachidonic acid trifluoromethyl ketone (AACOCF3), an inhibitor of  cPLA2, showed the 
highest negative enrichment score (Table 2). Immunohistochemistry showed that cPLA2 was present in all 
vascular areas in early- and late-stage CVD (Supplemental Figure 2A). Semiquantitative analysis showed 
that cPLA2 was significantly more abundant in the intima of  advanced- compared with early-stage CVD 
arteries, while no significant difference was observed in the tunica media and the tunica externa (Supplemen-
tal Figure 2B). Western Blot analysis confirmed that cPLA2 expression was significantly higher (1.4-fold) in 
arteries from advanced-stage CVD patients compared with early-stage CVD patients (Figure 2).
AACOCF3 protects against vascular calcification. Arterial calcifications are observed during medial cal-
cification and late-stage atherosclerosis (4, 14). Vascular smooth muscle cells (VSMCs) are important 
mediators for these calcific processes (4). Due to important clinical implications, we have focused our 
interventional approach on the effects of  AACOCF3 in VSMCs.
Table 1. Clinical parameters of the early- and advanced-stage CVD patients in whom high-resolution vessel proteome analysis was 
performed
Early-stage CVD Advanced-stage CVD
Mean SD Min Max nA Yes/no Mean SD Min Max nA Yes/no t test
Sex 14 M/1 F 15 9 M/8 F 17
Age (yr) 45.4 18.2 21 74 15 66.1 9.2 50 78 17 0.0018
Weight (kg) 80.9 9.6 62 95 15 74.5 11.0 60 100 17 0.0609
Height (cm) 1.77 0.09 1.60 1.90 15 1.69 0.08 1.58 1.82 17 0.0208
BMI 25.9 2.3 22 31 15 26.1 3.5 21 35 17 0.9699
Nicotine 1/7 5/9
HypertensionB 5/10 17/0
Family history of CVDC 0/7 2/8
Diabetes 0/15 5/12
Vascular disease 1/13 17/0
Left ventricular hypertrophy 0/14 6/11
Angina pectoris 0/15 2/15
Claudicatio intermittens 0/14 9/8
Myocardial infarction 0/14 2/15
Death from a CV event 1/13 8/9
Routine analysis
Creatine kinase (U/l) 518 731 39 2790 13 138 141 11 529 14 0.0886
Creatine kinase isoform MB (U/l) 21.5 10.3 10 40 13 18.2 9.7 5 39 14 0.4090
Lactate dehydrogenase (U/l) 296 111 164 556 13 204 87 128 471 14 0.0283
Troponin T (pg/ml) 112 181 3 597 13 62 106 3 354 15 0.4100
NT-proBNP (pg/ml) 117 88 5 283 10 74 91 4 233 8 0.4140
Creatinine (mg/dl) 1.0 0.3 1 2 14 0.9 0.3 1 2 17 0.1726
Na (mmol/l) 150 7 137 161 13 143 8 133 163 17 0.0074
K (mmol/l) 4.2 0.4 4 5 14 4.1 0.4 4 5 17 0.5596
Ca (mmol/l) 2.1 0.3 1 2 14 2.3 0.1 2 2 16 0.0114
Leukocytes (g/l) 11.3 3.2 7 17 14 10.5 4.3 5 21 17 0.5380
C-reactive protein (mg/l) 154 72 43 298 14 95 101 1 249 17 0.0677
Total bilirubin (mg/dl) 0.9 0.5 0 2 13 0.5 0.3 0 1 17 0.0300
Alanine transaminase (U/l) 74.2 64.4 12 221 13 33.1 40.4 8 158 12 0.0679
Aspartate transaminase (U/l) 75.2 47.4 23 196 13 31.5 23.5 14 100 13 0.0081
Cholinesterase (U/l) 4129 1241 2132 6418 13 6482 2823 1625 12333 16 0.0071
Total cholesterol (mg/dl) 115 69 31 280 13 132 21 106 168 7 0.4349
Triglycerides (mg/dl) 111 55 34 193 13 150 88 66 346 12 0.1956
An, measured patients; Bhypertension (≥140/90 mmHg); Cfamily history of CVD (CVD in first-degree relatives; women <65 years; men <55 years). Min, 
minimum; max, maximum; M, male; F, female.
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To evaluate the potential protective effects of  AACOCF3 on CVD, experiments were performed in the 
cholecalciferol-overload (cholecalciferol is also known as vitamin D3) mouse vascular calcification mod-
el without or with additional treatment with AACOCF3. Cholecalciferol overload significantly increased 
serum calcium, calcium × phosphorus (CaxPi) product, and FGF23 C-terminal concentrations and reduced 
serum phosphorus levels to similar levels in both control- and AACOCF3-treated mice (Table 3).
Cholecalciferol overload triggered aortic calcification in mice, an effect significantly attenuated by addi-
tional treatment with AACOCF3 (Figure 3A). In control mice, AACOCF3 did not modify aortic calcium 
deposition. The mRNA level of  the gene encoding the most prevalent cPLA2 subtype, cPLA2α (Pla2g4a) 
(15), was significantly higher in aortic tissue of  cholecalciferol-treated mice than in that of  control mice 
(Figure 3B). AACOCF3 treatment alone did not significantly affect aortic Pla2g4a mRNA expression. 
Western blot analysis showed that cPLA2 protein was clearly present in the aortic tissue, but no significant 
change was observed after vitamin D or AACOCF3 treatments (Supplemental Figure 3).
These effects were paralleled by inhibition of  aortic osteogenic/chondrogenic signaling by AACOCF3. 
As shown in Figure 4, cholecalciferol overload significantly upregulated mRNA expression of  osteogenic 
transcription factors Msx2 and Cbfa1 and of  osteogenic enzyme tissue-nonspecific alkaline phosphatase 
(Alpl), markers of  increased osteogenic/chondrogenic transdifferentiation in the aortic tissue, effects again 
significantly ameliorated by AACOCF3 treatment. Thus, AACOCF3 inhibited aortic osteoinductive sig-
naling and vascular calcification in the cholecalciferol-overload mouse model.
To investigate possible mechanisms of  the protective effects of  AACOCF3 on vascular calcification, 
further experiments were performed in primary human aortic smooth muscle cells (HAoSMCs) during 
high-phosphate conditions in the presence or absence of  AACOCF3. As shown by alizarin red staining and 
quantification of  calcium deposition, treatment with calcification medium increased calcification of  HAoS-
MCs that was significantly blunted by treatment with AACOCF3 (Figure 5, A and B). Similarly, AACOCF3 
significantly suppressed phosphate-induced MSX2, CBFA1, and ALPL mRNA expression (Figure 5, C–E) 
as well as ALPL activity (Figure 5F) in HAoSMCs. In control conditions, AACOCF3 did not significantly 
affect mineralization but tended to reduce CBFA1 mRNA levels (P = 0.202) and significantly downregulated 
MSX2 and ALPL mRNA expression in HAoSMCs (Figure 5, A–F). Thus, AACOCF3 suppressed phos-
phate-induced osteogenic/chondrogenic transdifferentiation and calcification of  HAoSMCs in vitro.
Moreover, phosphate triggered the release of  arachidonic acid (AA) in the cell culture medium of  
HAoSMCs (Figure 5G). Treatment with AACOCF3 significantly inhibited both basal and Pi-induced 
release of  AA, the product of  PLA2 activity.
Figure 1. Histology of human arteries. Representative images of H&E staining (A and C) and von Kossa staining (B and 
D) of iliac artery sections from an early- (A and B) and an advanced-stage (C and D) CVD patient. Black staining in B and 
D corresponds to calcium deposits. Scale bar: 500 μm.
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To confirm the involvement of  cPLA2 in vascular calcification, the endogenous expression of  
cPLA2 in HAoSMCs was suppressed by silencing of  the PLA2G4A gene using siRNA. As a result, 
transfection with cPLA2 siRNA significantly suppressed PLA2G4A mRNA levels in HAoSMCs, as 
compared with negative control-silenced HAoSMCs (Figure 6A). Phosphate treatment upregulated 
PLA2G4A mRNA expression in negative control-silenced HAoSMCs (Figure 6A). Furthermore, phos-
phate significantly increased MSX2, CBFA1, and ALPL mRNA expression in negative control siRNA–
transfected HAoSMCs, effects significantly blunted in cPLA2 siRNA silenced HAoSMCs (Figure 6, 
B–D). Taken together, the protective effects of  AACOCF3 on vascular calcification may involve, at 
least in part, inhibition of  cPLA2-mediated osteoinductive signaling.
AACOCF3 treatment of  ApoE–/– mice. AACOCF3 was tested in another preclinical model of  CVD, 
ApoE–/– mice known to develop atherosclerotic lesions. In our conditions, ApoE–/– mice fed a high-cho-
lesterol diet displayed dyslipidemia (Table 4, vehicle) and lipid deposition (Figure 7A) and increased 
type III collagen expression (Figure 7B) in the aortic sinus, in agreement with previous reports (16). 
Ten weeks of  treatment with AACOCF3 did not significantly modify plasma lipids and glucose levels 
(Table 4). In contrast, analysis of  the aortic root showed that AACOCF3 had no influence on the total 
Table 2. Top molecules predicted to reverse human arterial protein signature of advanced-stage CVD following CMap analysis
CMap name Mean n Enrichment p Specificity % Nonnull
Arachidonyltrifluoromethane –0.538 2 –0.918 0.01368 0.0261 100
Atracurium besilate –0.556 3 –0.915 0.00104 0 100
Prestwick-691 –0.542 3 –0.891 0.0025 0.0263 100
Vinblastine –0.551 3 –0.888 0.00268 0.0382 100
Isoflupredone –0.555 3 –0.871 0.00421 0.1083 100
Ouabain –0.48 4 –0.854 0.00084 0.0263 100
Viomycin –0.596 4 –0.849 0.00097 0.0576 100
STOCK1N-35696 –0.511 2 –0.846 0.04797 0.0616 100
Quinpirole –0.524 4 –0.827 0.00171 0 100
Ajmaline –0.559 3 –0.827 0.01024 0.0284 100
Lisuride –0.529 5 –0.816 0.00054 0.0082 100
Thioperamide –0.479 5 –0.791 0.00078 0 100
Mean represents the arithmetic mean of the connectivity scores for those signatures. n represents the number of signatures of a given compound 
available in the Cmap database. Enrichment indicates the degree of matching between a Query Signature (here, the CVD signature) and the reversed 
signature of a given compound. p (permutation p) estimates the likelihood that the enrichment would be observed by chance. Specificity provides 
a measure of the uniqueness of the matching between a compound and the CVD signature. The nonnull percentage measures the support for the 
connection between a set of compound signatures and the Query Signature based upon the behavior of the individual signature in that set. More details 
can be found here: https://portals.broadinstitute.org/cmap/help_topics_frames.jsp.
Figure 2. cPLA2 expression was increased in the arteries 
of advanced- compared with early-stage CVD patients. 
(A) Representative cPLA2 and GAPDH Western blots in 
iliac arteries from early- (n = 3) versus advanced-stage (n 
= 3) CVD patients. (B) Scatter dot plots (arithmetic mean 
± SEM) of cPLA2 protein expression normalized to GAPDH 
in iliac arteries from early- (n = 14) versus advanced-stage 
(n = 23) CVD patients. *P < 0.05 vs. early-stage CVD group 
(unpaired Mann-Whitney test).
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plaque area, but it significantly inhibited lipid deposition in the plaques (–35%; Figure 7A) compared 
with vehicle-treated mice. In parallel, AACOCF3 significantly reduced type III collagen plaque expres-
sion (–16%; Figure 7B) but had no significant influence on total collagen accumulation, as assessed 
by Sirius red staining (Supplemental Figure 4). In parallel, AACOCF3 did not changed αSMA (myo-
fibroblast marker) and significantly increased MOMA2 (macrophage marker) staining (Supplemental 
Figure 4). Finally, AACOCF3 did not significantly change the expression of  calcification gene markers 
(Alpl and Cbfa1) in aortic tissue (Supplemental Figure 5). Collectively, the experiments using the 
ApoE–/– mouse model showed that, while AACOCF3 reduces lipid accumulation, it has no effect on 
atherosclerotic lesions.
Discussion
In the present study, we explored the possibility of  omics-based disease signature correction by small bio-
active compounds to identify and validate in vivo CVD drugs. Applying this approach to the high-reso-
lution human arterial protein signature of  advanced-stage CVD, we identified among >1000 compounds 
the cPLA2 inhibitor AACOCF3 that reversed this CVD signature. AACOCF3 is a cell-permeant trifluo-
romethyl ketone analog of  AA (17) that behaves as a slow- and tight-binding inhibitor of  cPLA2 (18–21). 
A review of  the literature showed that cPLA2 inhibition has not been used in CVD management yet, 
suggesting AACOCF3 as a possible novel drug candidate for CVD treatment. Our preclinical analysis of  
the cholecalciferol-overload mouse model demonstrates that AACOCF3 was efficient in vivo at attenuat-
ing vascular calcification, one of  the major features of  CVD. To our knowledge, our work demonstrates 
for the first time the protective action of  AACOCF3 against vascular injury.
Functional analysis of  the proteins present in the human CVD vessel signature highlighted enrich-
ment of  proteins associated with cholesterol and lipid metabolism. Moreover, we also detected an increase 
in EFEMP1, also called fibulin-3, a protein involved in the regulation of  osteogenic/chondrogenic 
Table 3. Effect of AACOCF3 during cholecalciferol overload
CTR AAC vD vD + AAC n
Calcium (mg/dl) 10.29 ± 0.23 9.63 ± 0.23 20.01 ± 0.60A 19.00 ± 0.56A 5–6
Phosphorus (mg/dl) 7.78 ± 0.25 7.23 ± 0.55 5.53 ± 0.11A 5.81 ± 0.14B 5–6
CaxPi product 79.9 ± 1.8 69.6 ± 5.3 110.3 ± 2.0A 110.2 ± 3.1A 5–6
FGF23 C-terminal (pg/ml) 554 ± 52 525 ± 31 172980 ± 18530C 192196 ± 19727C 5–6
Arithmetic mean ± SEM of serum calcium, phosphorus, CaxPi product, and FGF23 C-terminal concentrations in mice receiving vehicle (CTR) or high-dosed 
cholecalciferol (vD), without or with additional treatment with AACOCF3 (AAC). AP < 0.001, BP < 0.01, CP < 0.05 vs. control mice.
Figure 3. AACOCF3 reduced vascular calcification in vivo. (A) Scatter dot plots (arithmetic mean ± SEM) (n = 5–6, 
μg/mg protein) of calcium content in aortic tissue of mice receiving vehicle (CTR) or high-dosed cholecalciferol (vD), 
without or with additional AACOCF3 (AAC) treatment. (B) Scatter dot plots (arithmetic mean ± SEM) (n = 5–6; arbitrary 
units [a.u.]) of Pla2g4a relative mRNA expression in aortic tissue of mice receiving vehicle or high-dosed cholecalcif-
erol, without or with additional AACOCF3 treatment. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control mice; †P < 0.05 vs. 
vD-treated mice (1-way ANOVA with Tukey-HSD post-hoc test).
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transdifferentiation of  VSMCs (22). Because vascular calcification is preferentially associated with 
advanced-stage CVD, we focused on the mechanisms of  AACOCF3 in this process. Vascular calcifica-
tion is mediated mainly by osteogenic/chondrogenic reprogramming of  VSMCs in response to various 
triggers, especially hyperphosphatemia (14, 23). In liver tissue, excessive phosphate intake in rats is 
associated with increased AA concentrations (24). The osteogenic/chondrogenic transdifferentiated 
VSMCs are characterized by increased expression and activity of  osteogenic and chondrogenic tran-
scription factors as well as of  osteogenic enzymes, such as tissue nonspecific ALPL, leading to active 
mineralization of  the vascular tissue (22, 25–27). We show here that AACOCF3 treatment attenuates 
vascular osteogenic/chondrogenic transdifferentiation and calcification in vitro and in the cholecalcif-
erol-overload mouse model in vivo. Moreover, vascular cPLA2 expression is increased during calci-
fication conditions, both in vitro and in vivo. Accordingly, osteogenic/chondrogenic transdifferentia-
tion of  VSMCs during elevated phosphate levels in vitro is blunted by silencing of  cPLA2, and, thus, 
cPLA2 knockdown mimics the protective effects of  AACOCF3. These observations strongly suggest 
that the in vivo protective effect of  AACOCF3 may result, at least partially, from its direct action on 
VSMCs through inhibition of  cPLA2-dependent osteoinductive signaling.
There exist multiple PLA2 isoforms classified as secreted (sPLA2) and cytosolic (cPLA2) that have 
different structures and various physiological functions. PLA2G4A, i.e., cPLA2, is a calcium-depen-
dent cPLA2. Some secreted isoforms, such as the lipoprotein-associated PLA2 (Lp-PLA2) or sPLA2-X 
or sPLA2-V (28), were shown as causative in atherosclerosis, and some of  their inhibitors were in 
clinical trials but did not reach the market (29). Expression of  cPLA2 has been previously found in 
arteries from atherosclerotic patients, mainly localized in the intimal regions with an inflammatory 
infiltrate consisting of  macrophages and smooth muscle cells (30). Our results confirm a localization 
of  cPLA2 in the intima, but the clinical relevance of  this observation remains to be established because 
immunolocalization was not assessed directly within atherosclerotic plaques. Moreover, a PLA2G4A 
gene variant was associated with a decreased risk of  coronary artery disease, although the functional 
consequence of  the mutation remains still elusive (31). Our results are in agreement with those obser-
vations, since we found that cPLA2 was indeed present in arteries and its expression was increased in 
advanced-stage CVD. So far, to our knowledge the use of  a cPLA2 inhibitor as a possible drug candi-
date for CVD treatment has never been proposed.
A first limitation of  our study is that we have deliberately compared patients with advanced vascular 
disease and early vascular disease. While these features were confirmed by histology, the initial screen 
was based on presence or absence of  risk factors, and, hence, differences in age, blood pressure, and 
other cardiovascular risk factors between the group are present. We cannot rule out that elements of  the 
proteomic data are driven by these risk factors rather than specifically by the vascular phenotype. How-
ever, by selecting patients with multiple risk factors and advanced disease, we believe that our findings 
represent a molecular signature of  advanced arteriosclerosis, rather than a single risk factor. A further 
Figure 4. AACOCF3 ameliorated aortic osteogenic/chondrogenic signaling during cholecalciferol overload–induced calcification in vivo. Scatter dot 
plots (arithmetic mean ± SEM) (n = 5–6; arbitrary units [a.u.]) of Msx2 (A), Cbfa1 (B), and Alpl (C) relative mRNA expression in aortic tissue of mice 
receiving vehicle (CTR) or high-dosed cholecalciferol (vD), without or with additional treatment with AACOCF3 (AAC). *P < 0.05, **P < 0.01 vs. control 
mice; †P < 0.05 vs. vD-treated mice (Steel-Dwass method for A and 1-way ANOVA with Games-Howell post-hoc test for B and C).
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limitation might be that the CVD signature was established from peripheral arteries (iliac and femoral) 
and cannot necessarily be extrapolated to a CVD signature in other arterial locations. However, our 
results show that AACOCF3 treatment was efficient in the aorta of  the animal models, suggesting that 
its protective action is not limited to peripheral arteries and that, apparently, the molecular mechanisms 
overlap between these different vessel compartments/segments. We are also aware that the specificity of  
AACOCF3 for cPLA2 is likely not exclusive. Indeed, it has been reported that AACOCF3 was able to 
inhibit cyclooxygenases 1 and 2 (32). However, our results show that the effect of  AACOCF3 could be 
reproduced by cPLA2 knockdown in vitro.
Figure 5. AACOCF3 suppressed phosphate-induced calcification and osteogenic/chondrogenic signaling in HAoSMCs. Representative images show-
ing alizarin red staining (A, n = 3) and scatter dot plots (arithmetic mean ± SEM) of calcium content (B, n = 4, μg/mg protein) in HAoSMCs following 
treatment with control (CTR) or with calcification medium (Calc.), without or with additional treatment with 10 μM AACOCF3 (AAC). The calcified areas 
are shown as red staining. (C–G) Scatter dot plots (arithmetic mean ± SEM) of MSX2 (C), CBFA1 (D), and ALPL (E) relative mRNA expression (n = 6;  
arbitrary units [a.u.]) and ALPL activity (F, n = 4, U/mg protein) in HAoSMCs as well as arachidonic acid (AA) levels (G, n = 4; ng/mg protein) in the 
cell culture medium of HAoSMCs following treatment with control or with β-glycerophosphate (Pi), without or with additional treatment with 10 μM 
AACOCF3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control-treated HAoSMCs; †P < 0.05, ††P < 0.01, †††P < 0.001 vs. HAoSMCs treated with Calc./Pi alone 
(1-way ANOVA with Games-Howell post-hoc test for B, C, and F or with Tukey-HSD post-hoc test for D, E, and G).
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In conclusion, using a systems biology approach to optimally describe the molecular mechanisms 
of  human advanced-stage CVD, we identified a potentially new compound that reversed typical vascu-
lar lesions in CVD in vivo. Apart from the clear effect of  this approach in CVD, such a strategy should 
be able to generate novel targets in other complex diseases.
Methods
Arterial sample acquisition and CVD grading method. 18 common iliac arteries, 15 superficial femoral arteries, 
and 2 external iliac arteries were collected from 15 early- and 17 advanced-stage CVD patients, with the 
following specific distribution: early-stage CVD (11 common iliac arteries, 2 external iliac arteries, 4 super-
ficial femoral arteries) and advanced-stage CVD (7 common iliac arteries, 11 superficial femoral arteries). 
All advanced-stage CVD patients had clear CVD phenotypes (vascular disease, left ventricular hypertrophy, 
angina pectoris, claudication intermittens, myocardial infraction). These cardiovascular phenotypes were 
not found early-stage CVD patients exhibits (Table 1). Following harvesting, the vascular tissues were snap 
frozen in liquid nitrogen and stored at –80°C until preparation for proteomics analysis. Blood and urine 
samples were also collected from the same patients for biochemical analysis.
Sample preparation and LC-MS/MS analysis. Approximately 10–20 mg (net weight) of tissue specimen was 
homogenized in lysis buffer consisting of 0.1 M Tris-HCl, pH 7.6, supplemented with 4% SDS and 0.1 M DTE. 
Figure 6. Silencing of cPLA2 inhibited phosphate-induced osteogenic/chondrogenic signaling in HAoSMCs. 
Scatter dot plots (arithmetic mean ± SEM) (n = 6, arbitrary units [a.u.]) of PLA2G4A (A), MSX2 (B), CBFA1 (C), and 
ALPL (D) relative mRNA expression in HAoSMCs following silencing with negative control siRNA (Neg.si) or cPLA2 
siRNA (cPLA2si), without or with additional treatment with β-glycerophosphate (Pi). *P < 0.05, **P < 0.01, ***P 
< 0.001 vs. Neg.si-silenced HAoSMCs; †P < 0.05, †††P < 0.001 vs. Neg.si-silenced and Pi-treated HAoSMCs (1-way 
ANOVA with Games-Howell post-hoc test for A or with Tukey-HSD post-hoc test for C and Steel-Dwass method 
for B and D).
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Homogenization was performed with the bullet blender homogenizer (Next Advance) (33). Ten micrograms of  
each protein sample were analyzed in SDS-PAGE (5% stacking, 12% separating). Electrophoresis was stopped 
when samples just entered the separating gel. Gels were fixed with 30% methanol, 10% acetic acid for 30 min-
utes, followed by 3 washes with water (5 minutes each), and stained with Coomassie colloidal blue overnight. 
Each band was excised from the gel and further sliced into small pieces (1–2 mm). Gel pieces were destained 
with 40% acetonitrile, 50 mM NH4HCO3 and then reduced with 10 mM DTE in 100 mM NH4HCO3 for 20 
minutes at room temperature. After reduction, samples were alkylated with 54 mM iodoacetamide in 100 mM 
NH4HCO3 for 20 minutes at room temperature in the dark. Samples were then washed with 100 mM NH4H-
CO3 for 20 minutes at room temperature, followed by another wash with 40% acetonitrile, 50 mM NH4HCO3 
for 20 minutes at room temperature and a final wash with ultrapure water under the same conditions. Gel piec-
es were dried in a centrifugal vacuum concentrator and trypsinized overnight in the dark at room temperature 
by adding 600 ng trypsin per sample (trypsin stock solution: 10 ng/μl in 10 mM NH4HCO3, pH 8.5). Peptides 
Table 4. Influence of AACOCF3 treatment on plasma lipids and glucose in ApoE–/– mice
Plasma concentration (mmol/l) Vehicle (n = 18) AACOCF3 (n = 18)
Total cholesterol 17.45 ± 0.73 17.55 ± 1.04
HDL cholesterol 0.30 ± 0.02 0.33 ± 0.02
LDL cholesterol 5.72 ± 0.26 5.66 ± 0.30
Triglyceride 1.67 ± 0.10 1.56 ± 0.15
Glucose 11.14 ± 0.57 11.45 ± 0.50
Figure 7. Influence of AACOCF3 treatment in ApoE–/– mice. Representative images and scatter dot plots (arithmetic 
mean ± SEM) of quantification (percentage) of lipid deposits by oil red O staining (A, n = 8–10) and of type III collagen 
by immunostaining (B, n = 7–11) in aortic sinus cryosections of 6-week-old ApoE–/– male mice fed a high-cholesterol diet 
and simultaneously treated with AACOCF3 (AAC, 10 mg/kg) or vehicle (CTR) for 10 weeks. *P < 0.05 vs. control mice 
(unpaired 2-tailed t test). Scale bar: 100 μm.
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were extracted after incubation with 50 mM NH4HCO3 for 15 minutes at room temperature, followed by 2 
incubations with 10% formic acid, acetonitrile (1:1) for 15 minutes at room temperature. Peptides were eluted 
in a final volume of 600 μl and filtered with PVDF filters (Merck Millipore) before dried in a centrifugal vacu-
um concentrator. Dried peptides were reconstituted in mobile phase A buffer (0.1% formic acid, pH 3.5) and 
processed with LC-MS/MS analysis.
2.5 μg of  protein digest was injected from each sample into a Dionex Ultimate 3000 RSLS nano flow 
system configured with a Dionex 0.1 × 20 mm 5 μm C18 nano trap column. The mobile phase was 2% 
ACN/0.1% formic acid with a flow rate of  5 μl/min. The analytical column was an Acclaim PepMap C18 
nano column, 75 μm × 50 cm, 2 μm 100 Å, at a flow rate of  300 nl/min. The trap and nano flow column 
were maintained at 35°C. The samples were eluted with a gradient starting at 1% B for 5 minutes, rising to 
5% B at 10 minutes, then to 25% B at 360 minutes, and 65% B at 480 minutes. Mobile phase A was 0.1% 
formic acid, while mobile phase B was 80% ACN/0.1% formic acid. The column was washed and reequil-
ibrated prior to each sample injection. The eluent was ionized using a Proxeon nano spray ESI source 
operating in positive ion mode. For mass spectrometry analysis, an Orbitrap LTQ Velos (Thermo Finnigan) 
was operated in MS/MS mode, scanning from 380 to 2,000 m/z. Ionization voltage was 2.6 kV, and the 
capillary temperature was 275°C. The resolution of  ions in MS1 was 60,000 and 7,500 for higher-energy 
collisional dissociation (HCD) MS2. The top 20 multiply charged ions were selected from each scan for 
MS/MS analysis using HCD at 35% collision energy. Dynamic exclusion was enabled with a repeat count 
of  1, exclusion duration of  30 seconds.
MS data processing and quantification. Raw files were analyzed with Proteome Discoverer 1.4 software pack-
age (Thermo Finnigan), using the Sequest search engine and the Uniprot human (Homo sapiens) reviewed 
database, downloaded on May 30, 2016. The search was performed using carbamidomethylation of  cysteine 
as static and oxidation of  methionine as dynamic modifications. Two missed cleavage sites, a precursor mass 
tolerance of  10 ppm and fragment mass tolerance of  0.05 Da were allowed. FDR validation was based on 
q values: target FDR (strict): 0.01, target FDR (relaxed): 0.05. Quantification analysis was performed at the 
peptide level, with the clustering approach as previously described (34), with some minor modifications. Pep-
tides were clustered using the “window” of  mass (±5 ppm) and retention time (±15 minutes). Only peptides 
present in 60% of the samples in at least 1 group were further processed for quantification and statistical anal-
ysis (Mann-Whitney). The differentially expressed proteins selected for further analysis were considered those 
with a fold change of  ≥1.2 or ≤0.83 in both batches and a P value of  ≤0.05 in at least 1 batch.
CMap analysis. Each upregulated and downregulated protein ID from the CVD signature was convert-
ed into gene ID and were analyzed with the bioinformatic tool CMap (build 02). CMap is a collection of  
genome-wide transcriptional expression signatures (6,100 treatment vs. vehicle control pairs) from cultured 
human cells (MCF7, PC3, and HL60) treated with 1,309 bioactive small-chemical molecules at varying 
concentrations and analyzed by simple pattern-matching algorithms (10).
Preparation of  AACOCF3 solutions. AACOCF3 was supplied by Cayman Chemical (item 62120). For in 
vivo treatments, the initial solution of  AACOCF3 (50 mg/5 ml ethanol) was concentrated to 250 mg/ml 
and 20 μl was diluted in 4 ml of  a 0.5% methylcellulose (Fisher Scientific, product 10246190) in water. That 
solution was used to treat the animals. For in vitro treatment with AACOCF3 (Cayman Chemical), 10 
mM stock solution in ethanol, was diluted to a final concentration of  10 μM in cell culture medium. Equal 
amounts of  vehicle were used as control.
Mouse model of  vascular calcification. Female C57BL/6 mice were treated with AACOCF3 (10 mg/kg) or 
its vehicle (methylcellulose 0.5% containing 0.5% M ethanol) via gavage and were fed a calcium-reduced 
diet (Altromin, C1031). Subsequently, mice were injected subcutaneously with 400,000 IU/kg BW of  chole-
calciferol (MilliporeSigma) or vehicle for 3 days (35, 36). After 6 days of  treatment, blood was collected 
by retroorbital puncture under isoflurane inhalation anaesthesia. The mice were immediately sacrificed by 
cervical dislocation, and aortic tissues were collected and snap frozen for further experiments.
Mouse model of  atherosclerosis. ApoE–/– mice (37, 38) (6-week-old males) (Charles River) were fed a high-cho-
lesterol diet (1.25% cholesterol, 6% fat, and 2% sucrose [Ssniff, Germany diet, TD.96335 mod. – 1.25% cho-
lesterol]) and simultaneously treated (gavage with 200 μl; 5 days a week) with AACOCF3 (10 mg/kg) or its 
vehicle (methylcellulose 0.5% containing 0.5% M ethanol) for 10 weeks. The mice were sacrificed by pentobar-
bital injection, and the heart aortic sinus was collected and snap frozen in liquid nitrogen for further analysis. 
Blood was collected 1 week before sacrifice by intracaudal puncture in heparinized tubes. Ice-cold blood was 
centrifuged for 5 minutes at 1500 g, and upper plasma phase was collected and immediately frozen at –80°C.
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Biochemical analysis. The plasma concentrations of  phosphorus and calcium were measured by the 
QuantiChrom Phosphate assay kit and QuantiChrom Calcium assay kit, respectively (BioAssay Sys-
tems). An ELISA kit was used to determine plasma concentrations of  FGF23 C-terminal (Immutop-
ics), according to the manufacturer’s instructions. Blood glucose concentration was measured using a 
glucometer (Roche Diagnostic). Plasma concentrations of  cholesterol and triglyceride were measured 
by autoanalyzer (Horiba Medical).
Immunohistology. For human, histologic paraffin sections of  iliac arteries samples were cut at 2 μm, 
mounted on charged slides, and stained with H&E and von Kossa for pathological evaluation. cPLA2 stain-
ing was performed on 1–2 μm paraffin sections of A. ilia communis samples of  histopathologically classified 
early (n = 15) and advanced (n = 24) patients, using a 1:50 dilution of  the rabbit anti-human PLA2G4A 
antibody (ProSci Incorporated). Heat-induced epitope retrieval was performed at pH 8. For detection, the 
EnVision+ System-HRP Labelled Polymer Anti-Rabbit kit (Dako) was used. Nuclei were counterstained with 
hematoxylin, and sections were coverslipped with gelatin. The expression levels of  cPLA2 were evaluated per 
tissue section (vessel cross section), distinguishing between the different vessel layers (tunica intima, tunica 
media, and tunica externa). The abundance of  cPLA2 was scored as follows: 0.5 for no expression, 1 for weak 
expression, 2 for moderate expression, and 3 for strong expression. Images were acquired using the AxioIm-
ager Z1 microscope (Carl Zeiss MicroImaging Inc.). All evaluations were performed in a blinded manner.
For aortic sinuses of  ApoE–/– mice, lipid accumulation and collagen expression were analyzed on serial 
cross-cryosections of  the heart as previously described (39). For lipid analysis, cryosections were post-fixed 
with formaldehyde and stained with oil red O and counterstained with hematoxylin. For collagen, cryosec-
tions were post-fixed with methanol/acetone and exposed to a type III collagen primary antibody (Acris, 
BP8014) and revealed with an anti-rabbit HRP secondary antibody (DAKO, 4010). Samples were imaged 
with a Nikon Y-FL microscope equipped with a computer-based imaging system. Staining was expressed 
as the percentage of  total sinus area. Reported intensities used for further statistical analysis correspond to 
the mean value of  5 sections per animal.
Western blot. Arteria iliaca communis samples of  histopathologically classified control (n = 15) and dis-
ease (n = 24) patients were homogenized in lysis buffer (Invitrogen) supplemented with proteinase inhib-
itors (Roche). Next, 30 μg protein was loaded on 10% SDS-polyacrylamide gels. EFEMP1, GUCY1B2, 
KDM5D, cPLA2, and SHMT1 were detected with a rabbit anti-human EFEMP1 antibody (1:1000, 
Abcam), rabbit anti-human GUCY1B2 antibody (1:500, Thermo Fisher Scientific), rabbit anti-human 
KDM5D (Jarid 1D, 1:5000, Novus Biologicals), rabbit anti-human PLA2G4A antibody (1:500, ProSci 
Incorporated), and rabbit anti-human SHMT1 (1 250, MilliporeSigma), respectively, followed by a goat 
anti-rabbit IR dye 680 secondary antibody (1:7500, LI-COR Biosciences). All samples were normalized 
toward GAPDH (1:2000, BPS Bioscience) as internal control. Visualization and quantitative analysis were 
performed on Odyssey (LI-COR Biosciences) via Odyssey V3.0 software (LI-COR Biosciences).
Cell culture of  primary HAoSMCs. Primary HAoSMCs (Thermo Fisher Scientific) were cultured in Way-
mouth’s MB 752/1 medium and Ham’s F-12 nutrient mixture in a 1:1 ratio (Thermo Fisher Scientific) con-
taining 10% FBS (Thermo Fisher Scientific) and 100 U/ml penicillin and 100 μg/ml streptomycin (Ther-
mo Fisher Scientific) (40, 41). HAoSMCs were used in all experiments from passages 4 to 11, and each 
experiment was performed in at least 2 different batches of  HAoSMCs at different passages, depending on 
the availability of  the cells. HAoSMCs were treated for 24 hours (qRT-PCR, AA release), 7 days (ALPL 
assay), or 11 days (calcification) with 2 mM β-glycerophosphate (MilliporeSigma) (25, 36, 40, 42, 43) or 
with 10 μM AACOCF3. Equal amounts of  vehicle were used as control. For the mineralization analysis 
and alizarin red staining, treatment with 10 mM β-glycerophosphate and 1.5 mM CaCl2 (MilliporeSigma) 
for 11 days was used as calcification media (44). Fresh media with agents were added every 2–3 days. 
HAoSMCs were transfected with 10 nM cPLA2 siRNA (Thermo Fisher Scientific, s10592) or with 10 nM 
negative control siRNA (Thermo Fisher Scientific, 4390843) using siPORT amine transfection agent (Ther-
mo Fisher Scientific) according to the manufacturer’s protocol. The cells were used 48 hours (qRT-PCR) 
after silencing, and silencing efficiency was determined by quantitative RT-PCR.
Analysis of  calcification. To quantify vascular calcification, abdominal aortic tissues were incubated over-
night at 37°C in 0.6 M HCl. HAoSMCs were incubated in 0.6 M HCl for 24 hours at 4°C. Calcium content 
in the supernatant was determined by using QuantiChrom Calcium assay kit (BioAssay Systems) accord-
ing to the manufacturer’s protocol. Tissues and HAoSMCs were lysed with 0.1 M NaOH/ 0.1% SDS and 
protein concentration was determined by the Bradford assay (Bio-Rad). The results are shown normalized 
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to total protein concentration (45). To visualize calcification, HAoSMCs were fixed with 4% paraformalde-
hyde and stained with 2% alizarin red (pH 4.5). The calcified areas are shown as red staining (36).
ALPL activity assay. ALPL activity in HAoSMCs was determined by using the ALP colorimetric assay 
kit (Abcam) according to the manufacturer’s protocol (22, 41). The results are shown normalized to total 
protein concentration measured by the Bradford assay (Bio-Rad).
AA release. Medium AA levels were determined by using an AA ELISA kit (Elabscience) according to 
the manufacturer’s instructions. The results are shown normalized to total protein concentration measured 
by the Bradford assay (Bio-Rad).
RNA isolation and quantitative RT-PCR. Total RNA was isolated from aortic tissue and HAoSMCs by 
using Trizol Reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions (46–48). 
Reverse transcription of  total RNA was performed using oligo(dT)12–18 primers (Thermo Fisher Scien-
tific) and SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). Quantitative RT-PCR was per-
formed with the iCycler iQ Real-Time PCR Detection System (Bio-Rad) and iQ Sybr Green Supermix 
(Bio-Rad) according to the manufacturer’s instructions. The mouse and human primer sequences are given 
in Supplemental Tables 1 and 2, respectively. The specificity of  the PCR products was confirmed by analy-
sis of  the melting curves. All PCRs were performed in duplicate, and relative mRNA expression was calcu-
lated by the 2–ΔΔCt method using GAPDH as housekeeping gene normalized to the control group.
Statistics. Proteomics statistical analysis was based on the Mann-Whitney test performed using R package. 
For both batches, protein changes between early-stage and advanced-stage CVD with P ≤ 0.05 were considered 
as statistically significant. For other statistical analysis, data are shown as scatter dot plots, with arithmetic 
mean ± SEM; n indicates the number of independent experiments performed at different passages of the cells 
or the number of mice examined, respectively. Normality was tested with the Shapiro-Wilk test. Nonnormal 
data sets were transformed (log, reciprocal, or sqrt) prior to statistical testing to provide normality according to 
the Shapiro-Wilk test. Statistical testing was performed by 1-way ANOVA followed by Tukey test for homosce-
dastic data or Games-Howell test for heteroscedastic data. Nonnormal data were tested by the Steel-Dwass 
method. Two groups were compared by unpaired 2-tailed t test or Mann-Whitney test. P < 0.05 was considered 
statistically significant (22).
Study approval. The study has been conducted according to the principles expressed in the Declaration 
of  Helsinki. Written informed consent has been provided by each patient or their representative. Human 
studies were reviewed and approved by the local ethics committee (Ethikkommission - Medizinische Uni-
versität Graz, Graz, Austria; approval 26–355 ex 13/14). All animal experiments were conducted accord-
ing to the recommendations of  the Guide for the Care and Use of  Laboratory Animals (National Academies 
Press, 2011) as well as the German law for the welfare of  animals and were approved by local authorities 
(ethics committee for animal experiment, G32217; Berlin, Germany). The project was approved by the 
local (Inserm/UPS US006 CREFRE) and national ethics committees (ethics committee for animal experi-
ment, CEEA122; Toulouse, France; approval 02604.02).
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